Chesterfield, MO, United States of America

Curtis A Spilburg

This inventor holds 20 USPTO granted patents and 3 published patent applications, plus 6 CIPO patents and 1 EPO patent. Top assignees: Cv Therapeutics, Inc., Monsanto Company, Zomanex, LLC. Active years: 1981-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Curtis A Spilburg. Retrieved from https://idiyas.com/inventor/curtis-a-spilburg

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 (Patent Applications = 3)

% Patents Active = 95.0

CIPO Patents = 6

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 2.1

ph-index = 8

Forward Citations = 236(Granted Patents)

Location History:

St. Louis, MO (US) (1981 - 1996)
Chesterfield, MO (US) (1987 - 1999)
Sunnyvale, CA (US) (1996 - 2006)
Hendersonville, NC (US) (2015)

Company Filing History:

6 out of 105

Cv Therapeutics, Inc.

4. 9 out of 834,513

Other

patents

Years Active: 1981-2015

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9107825 - Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs (2015-08-18),

2. 7071174 - Method and composition for inhibiting cholesterol esterase (2006-07-04),

3. 6632801 - Method and composition for inhibiting human cholesterol esterase (2003-10-14),

4. 5981299 - Mammalian pancreatic cholesterol esterase (1999-11-09),

5. 5792832 - Peptides from mammalian pancreatic cholesterol esterase (1998-08-11),

6. 5679375 - Method of treating ulcers with sulfated polysaccharides (1997-10-21),

7. 5624836 - DNA encoding bovine pancreatic cholesterol esterase (1997-04-29),

8. 5616570 - Use of non-absorbable synthetic sulfated polysaccharides to decrease (1997-04-01),

9. 5521303 - Method of manufacturing non-absorbable synthetic sulfated polysaccharides (1996-05-28),

10. 5492822 - Method for recovering purified 100,000 dalton molecular weight fraction (1996-02-20),

11. 5484777 - Pancreatic cholesterol esterase inhibitor (1996-01-16),

12. 5429937 - Method for recovering purified 100,000 molecular weight fraction of (1995-07-04),

13. 5352601 - Method for recovering purified 52,000 dalton fraction of human (1994-10-04),

14. 5173408 - Mammalian pancreatic cholesterol esterase (1992-12-22),

15. 5063210 - Use of sulfated polysaccharides to decrease cholesterol and fatty acid (1991-11-05),

Title: The Innovative Mind of Curtis A. Spilburg

Introduction

Curtis A. Spilburg, an accomplished inventor based in Chesterfield, MO, has made significant contributions to the field of biochemistry through his innovative inventions. With a remarkable portfolio of 19 patents, Spilburg's work primarily focuses on methods to inhibit cholesterol esterase, showcasing his dedication to improving human health.

Latest Patents

Among his notable inventions is the patent for a "Method and composition for inhibiting cholesterol esterase." This invention describes techniques for producing purified, high molecular weight sulfated polysaccharide compositions that effectively inhibit pancreatic cholesterol esterase and reduce cholesterol levels in the bloodstream. Another significant patent by Spilburg is the "Method and composition for inhibiting human cholesterol esterase." This patent details a therapeutic approach that includes ingesting a high molecular weight sulfated polysaccharide, designed to inhibit human cholesterol absorption, while maintaining strict standards on molecular weight and inorganic sulfate content.

Career Highlights

Over the years, Curtis A. Spilburg has been associated with various companies, including Cv Therapeutics, Inc., where he has furthered his research and development efforts. His expertise in biochemistry and his innovative approach have allowed him to secure a prominent position in the scientific community through his numerous patents.

Collaborations

Throughout his career, Spilburg has collaborated with other prominent figures in the field, including Louis G. Lange, III, and William M. Moore. These partnerships have likely contributed to the depth and impact of his research, allowing for shared insights and developments in the realm of cholesterol inhibition.

Conclusion

Curtis A. Spilburg exemplifies the spirit of innovation and dedication to scientific research. With his extensive patent portfolio and collaborative efforts, Spilburg continues to be a vital contributor to our understanding of cholesterol management and the development of therapeutic solutions. His work not only enhances scientific knowledge but also has the potential to improve health outcomes for many individuals.

Profile summary based on public USPTO records.